Loading...
RLAY logo

Relay Therapeutics, Inc.NasdaqGM:RLAY Rapporto sulle azioni

Cap. di mercato US$2.3b
Prezzo delle azioni
US$13.02
US$22.83
43.0% sottovalutato sconto intrinseco
1Y355.2%
7D-1.5%
Valore del portafoglio
​
Vista

Relay Therapeutics, Inc.

Report azionario NasdaqGM:RLAY

Capitalizzazione di mercato: US$2.3b

Relay Therapeutics (RLAY) Panoramica del titolo

Relay Therapeutics, Inc. opera come azienda di farmaci di precisione in fase clinica. Maggiori dettagli

RLAY analisi fondamentale
Punteggio fiocco di neve
Valutazione2/6
Crescita futura2/6
Prestazioni passate0/6
Salute finanziaria6/6
Dividendi0/6

Premi

Si prevede che i ricavi cresceranno 62.28% all'anno

Gli utili sono cresciuti del 1.1% all'anno negli ultimi 5 anni

Gli analisti concordano sul fatto che il prezzo delle azioni salirà di 75.4%

Analisi del rischio

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni


RLAY Community Fair Values

Create Narrative

See what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Concorrenti di Relay Therapeutics, Inc.

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Relay Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azioneUS$13.02
Massimo di 52 settimaneUS$17.32
Minimo di 52 settimaneUS$2.75
Beta1.75
Variazione di 1 mese-20.61%
Variazione a 3 mesi46.95%
Variazione di 1 anno355.24%
Variazione a 3 anni12.53%
Variazione a 5 anni-59.41%
Variazione dall'IPO-62.85%

Notizie e aggiornamenti recenti

Seeking Alpha • May 20

Relay Therapeutics: Zovegalisib Is Becoming A Platform In Disguise

Summary Relay Therapeutics is undervalued as the market overlooks its potential to build a multi-indication PI3Kα inhibitor franchise beyond breast cancer. Zovegalisib's Breakthrough Therapy designation and strong Phase 3 data support its differentiated tolerability and efficacy profile, targeting both oncology and vascular anomalies. RLAY's $642M cash position, recent ATM raise, and cost controls provide runway into 2029, enabling pivotal trials and pipeline expansion without near-term financing risk. I remain bullish as RLAY transitions from a single-asset narrative to a platform company leveraging mutant-selective PI3Kα inhibition across large, underserved patient populations. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • May 20

Relay Therapeutics: Zovegalisib Is Becoming A Platform In Disguise

Summary Relay Therapeutics is undervalued as the market overlooks its potential to build a multi-indication PI3Kα inhibitor franchise beyond breast cancer. Zovegalisib's Breakthrough Therapy designation and strong Phase 3 data support its differentiated tolerability and efficacy profile, targeting both oncology and vascular anomalies. RLAY's $642M cash position, recent ATM raise, and cost controls provide runway into 2029, enabling pivotal trials and pipeline expansion without near-term financing risk. I remain bullish as RLAY transitions from a single-asset narrative to a platform company leveraging mutant-selective PI3Kα inhibition across large, underserved patient populations. Read the full article on Seeking Alpha
Articolo di analisi • Apr 30

Analysts Are Betting On Relay Therapeutics, Inc. (NASDAQ:RLAY) With A Big Upgrade This Week

Shareholders in Relay Therapeutics, Inc. ( NASDAQ:RLAY ) may be thrilled to learn that the analysts have just delivered...
Articolo di analisi • Apr 12

Here's Why We're Watching Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Feb 14

Relay Therapeutics: A Precision Oncology Play Worth The Risk

Summary Relay Therapeutics focuses on selective small-molecule inhibitors, with RLY-2608 showing promise in breast cancer and a solid cash position lasting into 2027. Financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns about expense control and sustainable cash flow. Out-licensing RLY-4008 to Elevar Therapeutics secures up to $500 million in milestones, allowing RLAY to concentrate on RLY-2608's clinical trials. RLY-2608's early data is promising, but pivotal trials will determine its success in overcoming resistance and meeting regulatory expectations. Read the full article on Seeking Alpha
Articolo di analisi • Dec 19

We're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 01

Relay Therapeutics Has Interesting Science That Needs To Be Proven In Trials

Summary Relay Therapeutics has a promising 4D drug design platform but faces challenges with limited clinical data and high R&D expenses. Despite a strong IPO and substantial cash reserves, the stock has declined due to underwhelming trial results. RLY-4008 shows potential with positive early data, while RLY-2608 has been less impressive, causing market skepticism. With a cash runway of 6-7 quarters, the company needs significant positive data to regain investor confidence. Read the full article on Seeking Alpha
Seeking Alpha • Sep 11

Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations

Summary Relay Therapeutics’ Dynamo platform combines machine learning and physics-based simulation to target dynamic protein conformations for oncology and genetic disease therapies. RLY-2608 targets PI3Kα-mutated HR+/HER2- breast cancer, with promising Phase 2 results and potential approval by 2026-2027. The company’s RLY-4008 targets FGFR2-altered cholangiocarcinoma, and it is seeking pivotal trials and a commercialization partner to unlock broader market potential. Relay has up to 3.3 years cash runway (including the recent equity raise), which, I believe, is sufficient to cover the RLY-2608's upcoming milestones. Despite trial disappointments and potential dilution risks, RLAY's promising pipeline and robust financials justify a "buy" rating for long-term investors. Read the full article on Seeking Alpha
Articolo di analisi • Aug 03

Here's Why We're Not Too Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Articolo di analisi • Apr 17

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%

The latest analyst coverage could presage a bad day for Relay Therapeutics, Inc. ( NASDAQ:RLAY ), with the analysts...
Seeking Alpha • Mar 13

Relay Therapeutics: Platform More Important Than Programs

Summary Relay is a precision medicine company with a focus on understanding protein dynamics. The company is developing small molecule drugs for oncology, but its platform has broader applicability. Relay's stock has declined significantly since listing due to the combination of a difficult macro environment and a lack of positive clinical data. Sentiment appears to be overly bearish given Relay's long-term potential, although it could take the company several years to build data that supports its approach. Read the full article on Seeking Alpha
Seeking Alpha • Feb 13

Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag

Summary Relay Therapeutics is a biotech company focused on developing small molecule inhibitors for cancer treatment. Their lead agent, lirafugratinib, is being tested for intrahepatic cholangiocarcinoma and has shown promising results in early clinical studies. The company also has a pipeline project targeting mutated PI3K-alpha and another molecule, GDC-1971, which has been outlicensed to Genentech. Read the full article on Seeking Alpha
Articolo di analisi • Jan 21

Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

Today is shaping up negative for Relay Therapeutics, Inc. ( NASDAQ:RLAY ) shareholders, with the analysts delivering a...
Articolo di analisi • Nov 14

We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Jun 08

Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Articolo di analisi • Feb 22

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Articolo di analisi • Oct 23

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Sep 30

Relay set to Equal Weight at Barclays; says fairly valued ahead of catalysts

Barclays has launched its coverage on Relay Therapeutics, Inc. (NASDAQ:RLAY) with an Equal Weight rating and a $23 price target, noting that the Cambridge, Massachusetts-based biotech remains fairly valued despite upcoming catalysts. The analyst Peter Lawson awaits initial data expected in 1H 2023 from RLY-2608, one of RLAY’s lead candidates targeted at breast cancer. Lawson projects Phase 1 data from the mutant-PI3Ka inhibitor program to indicate more than 40% overall response rate (ORR) in HR+/HER2- breast cancer with a robust safety profile. The analysts also added that the development of RLY-4008, an inhibitor of fibroblast growth factor receptor 2, could expand into other tumors adding further upside to the stock. Seeking Alpha contributor Edmund Ingham thinks that RLAY could win FDA’s accelerated approval for RLY-4008 in bile duct cancer as early as next year.
Seeking Alpha • Sep 18

Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform

Summary Relay Therapeutics completed what was at the time the 3rd largest Biotech IPO in history in 2020, raising $400m. The company promised to use cutting edge AI driven technology to identify and develop drug targets with a primary focus on precision oncology. Its share price tanked during a tough biotech bear market, but it is +70% across the past 3 months. Data from its first clinical candidate RLY-4008 targeting bile duct cancer was exceptionally strong, and an accelerated approval could happen next year. A breast cancer franchise is potentially a blockbuster opportunity in 3-5 years time. I am keeping the faith. Investment Thesis I have covered Relay Therapeutics (RLAY) twice before for Seeking Alpha, once in September 2020, when I recommended the recently IPO'd company at a price of $35 per share, and later, in February 2021, when I again suggested the company was a "Buy", at $43 per share. Relay's IPO in July 2020 raised $400m at a price of $20m making it the third largest biotech of all time. The company - seeded via the biotech accelerator Third Rock Ventures, which also helped seed the likes of CRISPR gene editing specialist Editas Medicine (EDIT), central nervous system ("CNS") disorder drug developer Sage Therapeutics (SAGE), and Sickle Cell Disease pioneer Global Blood Therapeutics (GBT) - recently acquired by Pfizer (PFE) in a $5.4bn deal - is engaged in "next generation drug discovery". What that means is that Relay uses cutting edge biochemistry and biophysics techniques and advanced AI simulation to try to discover new drug targets and turn these targets into new drugs with superior efficacy and safety profiles than current standards of care. To simplify, Relay uses a 3-step drug discovery process that begins with a "modulation hypothesis", followed by "hit identification", followed by "lead optimisation". The problem with starting at the very beginning of the drug development process is that it takes years to advance into the clinic, let alone into pivotal trials or submitting a New Drug Application ("NDA") or Biologics Licence Application ("BLA") to the FDA seeking commercial approval. Frankly, during the savage bear run that saw the SPDR S&P Biotech ETF fall from an all-time high of $167 in February 2021, to a 5-year low of $67 in June this year, investors lost faith in early stage drug developers, focusing on the high cash burn and remote chances of near-term revenue generation, instead of the potential to develop blockbuster (>$1bn sales per annum) in the future. Relay was no exception - its share price fell from a January high of $61, to a June 2022 low of $14 - a loss of >75%. Overall, companies that have listed after being seeded by Third Rock have performed almost universally badly - most have lost between 10% - 85% of their value since IPO - but now that the worst bear market in biotech history appears to be over, the underlying investment cases behind these companies are worth revisiting. In Relay's case, for example, the company is now working with 3 clinical stage assets, and remarkably, is now on a pathway to a potential accelerated approval of its lead candidate RLY-4008 in bile duct cancer, or cholangiocarcinoma ("CCA"), after producing some stellar results in a Phase 1 trial. This rapid progress has seen Relay's share price make some upward progress - climbing by 69% across the past 3 months, from $14 to $23.5 at the time of writing. Relay began life with a substantial market cap valuation - when I covered the company in February 2021 it stood at $3.7bn - and it now stands at $2.55bn, so investors should not get too carried away. The bile duct cancer market is apparently worth only a couple of hundred million dollars so even if RLY-4008 were approved - perhaps as early as next year - the drug will not justify a $2.5bn market cap on its own. It will serve as a strong validation of Relay's approach however, and its ability to target proteins with greater specificity and accuracy than rival drug developers, and there are also plenty of expansion opportunities for a drug targeting Fibroblast growth factor receptor 2 ("FGFR2"), a gene and protein involved in cell signalling and proliferation. In this post I will take a closer look at the RLY-4008 data, discuss the opportunity in some more detail, and discuss whether Relay can have similar success with the 7 other programs it is actively working on. RLY 4008 Wows at ESMO - Agrees On Registrational Trial Protocol Relay presented its latest RLY-4008 data at the European Society for Medical Oncology, and the data can also be found in this post ESMO presentation. First of all, the drug demonstrated a favourable tolerability and safety profile across 195 patients, emphasising its ability to target FGFR2 with high selectivity i.e. not interfering with the processes of other genes and proteins and causing unintended damage to patients. Efficacy wise RLY-4008 appears to have been a slam dunk. The drug achieved an Objective Response Rate ("ORR") of 88% - 15 of 17 patients - at its pivotal 70mg dose, and a 63% ORR - 24 of 38 patients. Performance of approved FGFR inhibitors as 2nd line therapies. (Relay ESMO presentation) Source: Relay ESMO presentation. In the above table we can see the much lower response rates achieved by, respectively, Incyte's Pemazyre (Pemigatinib), approved for CCA in April 2020, and making $37m sales in H122, BridgeBio's (BBIO) Truseltiq, approved in June 2021 for CCA (sales data unavailable), Taiho Oncology's Futibatinib (not yet approved), and Johnson & Johnson (JNJ) subsidiary Erdafitinib, approved in 2019 for bladder cancer, and pegged for blockbuster sales. It is never necessarily a good idea to compare trial data, but it is hard to ignore the apparent superiority of RLY-4008 in terms of both safety and efficacy over its potential competitors. Relay's Phase 2 trial as agreed with FDA. (Relay ESMO presentation) Source: ESMO presentation. As above, the Phase 2 study which can potentially secure RLY-4008 will look at patients who are FGFR treatment naive primarily, but also patients who have already had some form of FGFR therapy, and those who have had no prior treatment of any kind, potentially bringing an approval as a first line therapy into play. Admittedly, none of the patients treated with RLY-4008 have experienced a complete response ("CR") - most have experienced a confirmed partial response, but 13 out of 15 patients receiving the 70mg dose remain on treatment, with one patient experiencing 68% tumor regression. It seems that however you slice and dice the Phase 1 data it looks impressive, and superior to what is currently on the market. There may be opportunities outside of CCA also - breast cancer is one other type of solid tumor in which early signs of activity have been observed. Building a Potential Breast Cancer Franchise As mentioned, RLY-4008 may provide some valuable validation of Relay's approach, technology, and cash burn - the company made a net loss of $138m in 1H22, and a $235m loss in the prior year period - but it is unlikely to drive much more than $100m - $200m of revenues in its CCA indication, if approved. Responsibility for opening up a far larger market in breast cancer - 195k patients are diagnosed with either HR+, or HER2- breast cancer annually in the US - falls primarily to RLY-2608 - a pan mutant selective allosteric inhibitor - supported by 2 other candidates - a selective CDK2 inhibitor, and an ERα Degrader. Targeting the allosteric sites on proteins - harder to reach, but offering more fertile ground for inhibitors, meaning better efficacy and greater selectivity - and protein degradation - marking oncogenic proteins for destruction by the immune system - are the types of approaches that allowed the likes of Relay, Kymera Therapeutics (KYMR), and Black Diamond Therapeutics (BDTX) to raise hundred of millions of dollars in the public markets, so it is encouraging to see Relay's early work begin to take shape. Relay says that RLY-2608 is the first known allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Kα, inhibitor in clinical development, and in April 2022, Relay initiated the second arm of the dose escalation part of a Phase 1 trial, evaluating RLY-2608 in combination with fulvestrant for patients with HR+, HER2–, PI3Kα-mutated, locally advanced or metastatic breast cancer. We don't have much in the way of data yet, but once again the efficacy and safety bar to beat is not a high one, Relay suggests, as per the table below. Overview of competitor PI3Kα data. (Relay ESMO presentation) Source: ESMO Presentation. A somewhat simplistic thesis goes that if Relay repeats its success with RLY-4008 data with RLY-2608, and the gates of a major oncology opportunity swing open. Pfizer's Ibrance achieved sales of >$6bn treating metastatic breast cancer last year, whilst Roche's (OTCQX:RHHBY) Herceptin made sales of ~$4bn. Ibrance is an inhibitor of CDK 4/6 - Relay's second breast cancer targeting drug inhibits CDK2, and is expected to begin clinical trials in 4Q23, or 1Q24, whilst the degrader candidate will be nominated in 2023. Conclusion - Relay's Early Data Shows It Can Prove The Doubters Wrong As mentioned, despite the heavy share price losses across the past year, Relay is still valued at $2.6bn, whilst the only drug likely to be approved within the next 3 years likely has a peak sales opportunity <$200m, which would arguably suggest Relay remains overvalued.
Seeking Alpha • Sep 09

Why did Relay Therapeutics stock drop today?

The shares of the clinical stage biotech Relay Therapeutics, Inc. (NASDAQ:RLAY) fell on Friday after an announcement of an abstract containing Phase 1/2 data for its bile duct cancer therapy RLY-4008 sent company shares sharply higher a day earlier. With data suggesting an ~88% of overall response rate (ORR) for a key objective of the trial, RLAY shares jumped more than 20% to reach a five-month high on Thursday. However, the rally proved brief as an SEC filing indicated that company director Mark Murcko sold 25K RLAY shares for more than ~$748K. With the sale, Murcko, a senior lecturer in the Department of Biological Engineering at MIT and a former chief technology officer at Vertex Pharma (VRTX), has reduced his stake in RLAY by ~2%. However, the company shares dropped regardless as the management prepares for an oral presentation of the abstract on Sunday at the ongoing ESMO Congress in France.

Rendimenti per gli azionisti

RLAYUS BiotechsUS Mercato
7D-1.5%-3.0%-0.3%
1Y355.2%32.9%26.7%

Ritorno vs Industria: RLAY ha superato il US Biotechs che ha restituito 32.9 % nell'ultimo anno.

Rendimento vs Mercato: RLAY ha superato il mercato US che ha restituito 26.7 % nell'ultimo anno.

Volatilità dei prezzi

Is RLAY's price volatile compared to industry and market?
RLAY volatility
RLAY Average Weekly Movement10.4%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.2%

Prezzo delle azioni stabile: RLAY non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.

Volatilità nel tempo: La volatilità settimanale ( 10% ) di RLAY è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
2015193Sanjiv Patelwww.relaytx.com

Relay Therapeutics, Inc. opera come azienda di farmaci di precisione in fase clinica. Trasforma il processo di scoperta dei farmaci, concentrandosi sul miglioramento della scoperta di terapie a base di piccole molecole in indicazioni mirate per l'oncologia e le malattie genetiche. I candidati principali dell'azienda includono RLY-2608, un inibitore pan-mutante e isoforme-selettivo della fosfoinostide 3 chinasi alfa, o PI3Ka, in fase di sviluppo clinico per il trattamento del cancro al seno, dei tumori solidi e delle malformazioni vascolari; e un chaperone aGal per le malattie di Fabry.

Relay Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Relay Therapeutics con la sua capitalizzazione di mercato?
RLAY statistiche fondamentali
Capitalizzazione di mercatoUS$2.31b
Utili (TTM)-US$272.70m
Ricavi(TTM)US$10.68m
233.7x
Rapporto P/S
-9.1x
Rapporto P/E

RLAY è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
RLAY Conto economico (TTM)
RicaviUS$10.68m
Costo del fatturatoUS$256.26m
Profitto lordo-US$245.58m
Altre speseUS$27.12m
Utili-US$272.70m

Ultimi utili riportati

Mar 31, 2026

Prossima data di guadagno

n/a

Utile per azione (EPS)-1.42
Margine lordo-2,300.34%
Margine di profitto netto-2,554.37%
Rapporto debito/patrimonio netto0%

Come si è comportato RLAY nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/20 13:10
Prezzo dell'azione a fine giornata2026/05/20 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Relay Therapeutics, Inc. è coperta da 18 analisti. 10 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Peter LawsonBarclays
Etzer DaroutBarclays
Gaurav GoparajuBerenberg